Bipolar Disorder

Dr Moukaddam shares factors to consider when approaching the treatment of bipolar disorder.

Nidal Moukaddam, MD, PhD, presents the case of a 30-year-old male diagnosed with bipolar 1 disorder and shares her initial impressions on diagnosis.

Researchers performed a randomized controlled trial of a high n-3, low n-6 polyunsaturated fatty acid diet in bipolar disorder.

Lithium for bone health? Researchers performed a retrospective cohort study to evaluate the effects of lithium on risk of osteoporosis in bipolar disorder.

Evidence review focuses on bipolar disorder, psychosis, and major depression.

How is this new drug going to help in the treatment of agitation in patients with schizophrenia or bipolar disorder?

Here are a few reminders to help avoid both toxicity and loss of effectiveness.

The FDA has approved dexmedetomidine sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

ECT played an important role in this patient's journey to recovery.

Today is World Bipolar Day! Celebrate with the freshest clinical pearls on bipolar disorder that Psychiatric Times has to offer.

Predicting mania versus psychosis: Researchers performed a retrospective study of prodromal symptoms, risk factors, and vulnerability markers in first-episode mania and psychosis.

Researchers performed an RCT of pramipexole for patients with bipolar disorder and cognitive impairment.

Although research is limited, the results are promising.

Two forms of telehealth can improve quality of life and care for patients with PTSD and bipolar disorder who live in more rural communities.

Treatment decisions lie on a continuum—befitting a dimensional approach to diagnosis.

Alkermes announced positive results from their phase 3b ENLIGHTEN-Early study.

Exploring cognitive biases toward the DSM and their avoidable effects on treatment decisions.

Sleep, depression, and bipolar disorder: what's the connection?

Sleep disturbances in borderline personality disorder are relatively unrecognized.

Have you had difficulty with differential diagnosis when patients have manic symptoms and psychosis? One doctor discusses the related DSM-5 criteria changes and some of their implications for psychopharmacology.

Patients weigh in on their experiences living with and receiving treatment for the disorder.

Caplyta is now FDA-approved for depressive episodes from bipolar I and II.

This infrequent, but important, toxic effect of lithium deserves increased awareness.

Need a recap of the custom Around the Practice video program on bipolar disorder? We've got you covered.